Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decode the science, funding outlook, and trial milestones inside MAIA Biotechnology’s SEC paperwork can be overwhelming. If you’ve ever typed “MAIA Biotechnology insider trading Form 4 transactions” or “MAIA Biotechnology quarterly earnings report 10-Q filing,” you know the raw documents rarely answer questions quickly. Oncology pipeline updates, dilution risks, and cash runway figures are scattered across hundreds of pages and multiple form types.
Stock Titan solves that challenge in one view. Our AI reviews every submission to EDGAR the moment it appears, converting dense language into concise insights. Whether you need “MAIA Biotechnology Form 4 insider transactions real-time” alerts that flag executive buys and sells, or a dashboard of “MAIA Biotechnology SEC filings explained simply,” our platform delivers context that matters. Looking for fast “MAIA Biotechnology earnings report filing analysis” without wading through footnotes? AI summaries pair the latest 10-Q numbers with historical trends so you can spot changes in R&D spend or cash burn instantly.
- Save hours understanding MAIA Biotechnology SEC documents with AI.
- Monitor MAIA Biotechnology executive stock transactions Form 4 before material announcements.
- Read the MAIA Biotechnology annual report 10-K simplified for pipeline risks and patent positions.
- Compare pay packages via the MAIA Biotechnology proxy statement executive compensation.
- Stay informed with MAIA Biotechnology 8-K material events explained whenever trial data or financing news breaks.
From insider trades to clinical readouts, every filing arrives with plain-English explanations, real-time updates, and exportable data—giving biotech investors the clarity they need to act decisively.
MAIA Biotechnology (NYSE:MAIA) filed an 8-K disclosing a Stock Purchase Agreement signed 24 Jun 2025 with Prevail Partners.
MAIA will issue up to $587,905 in common shares: a $58,800 upfront block and 36 equal tranches of $14,697. Shares price at 120% of the 30-day VWAP, but not below $1.74; at this floor the maximum issuance is 337,876 shares. A 19.99% ownership blocker prevents Prevail from exceeding that stake. The unregistered sale (Sections 4(a)(2)/3(a)(9)) qualifies as a Material Definitive Agreement (Item 1.01) and Unregistered Sales of Equity Securities (Item 3.02).
Proceeds will pay Prevail Infoworks for technology and services tied to MAIA’s Phase 3 THIO + cemiplimab lung-cancer trial, providing non-cash financing while introducing moderate dilution.
MAIA Biotechnology (NYSE: MAIA) announced the appointment of new members to its Scientific Advisory Board on June 24, 2025. The company, an emerging growth company listed on NYSE American, filed this 8-K to disclose the board expansion.
Key aspects of the filing include:
- The announcement was made through a press release (Exhibit 99.1)
- The company maintains its headquarters at 444 West Lake Street, Chicago
- The filing includes standard forward-looking statements highlighting potential risks in areas such as:
- Clinical study initiation, timing, and results
- Regulatory approval processes
- Product development and manufacturing capabilities
- Market acceptance and commercialization potential
- Intellectual property protection
The document was signed by Vlad Vitoc, Chief Executive Officer of MAIA Biotechnology.
FAQ
What is the current stock price of MAIA Biotechnology (MAIA)?
What is the market cap of MAIA Biotechnology (MAIA)?
What is MAIA Biotechnology Inc.'s primary focus?
How does the company manage its drug development risks?
What is the THIO program at MAIA Biotechnology?
How does MAIA Biotechnology differentiate itself from competitors?
What role does the management team play in the company?
How does MAIA Biotechnology support clinical research initiatives?
What are the key therapeutic areas MAIA Biotechnology targets?
